健脾通络方联合化疗对中晚期食管癌患者生活质量的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.1

基金项目:


Effect of Jianpi Tongluo Prescription Combined with Chemotherapy on Quality of Life in Patients with Advanced Esophageal Carcinoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探究健脾通络方联合化疗对中晚期食管癌患者的临床疗效以及对患者生活质量的影响。方法:选取中晚期食管癌患者83例,按随机数字表法分为对照组40例和观察组43例。对照组给予常规化疗治疗,观察组在对照组基础上加用健脾通络方进行治疗。比较2组临床疗效、中医证候积分和生活质量。结果:观察组总有效率为88.37%,高于对照组67.50%,差异有统计学意义(P<0.05)。治疗前,2组中医证候积分比较,差异无统计学意义(P>0.05)。治疗后,2组中医证候积分较治疗前降低,且观察组中医证候积分低于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组CD4+、CD4+/CD8+水平较治疗前升高,CD8+较治疗前下降(P<0.05);对照组CD4+、CD4+/CD8+水平较治疗前下降,CD8+较治疗前升高(P<0.05)。观察组CD4+、CD4+/CD8+水平高于对照组,CD8+水平低于对照组(P<0.05)。治疗前,2组卡氏评分比较,差异无统计学意义(P>0.05)。治疗后,2组卡氏评分较治疗前升高,且观察组卡氏评分高于对照组,差异均有统计学意义(P<0.05)。治疗前,2组生活质量评分比较,差异无统计学意义(P>0.05)。治疗后,2组生活质量评分较治疗前升高,且观察组生活质量评分高于对照组,差异均有统计学意义(P<0.05)。结论:健脾通络方联合化疗能有效减轻中晚期食管癌患者的临床症状,增强患者免疫功能,改善患者生活质量。

    Abstract:

    Abstract: Objective: To discuss the clinical effect of Jianpi Tongluo prescription combined with chemotherapy for patients with advanced esophageal carcinoma and its effect on quality of life. Methods:A total of 83 cases of patients with advanced esophageal carcinoma were divided into the control group and the observation group according to the random number table method, 40 and 43 cases in each group respectively. The control group was treated with routine chemotherapy,and the observation group was additionally treated with Jianpi Tongluo prescription based on the treatment of the control group. The clinical effect in the two groups was compared, and the Chinese medicine syndrome scores and quality of life in the two groups were observed. Results:The total effective rate was 88.37% in the observation group,higher than that of 67.50% in the control group, the difference being significant(P<0.05). Before treatment, there was no significant difference being found in the comparison of Chinese medicine syndrome scores between the two groups(P>0.05). After treatment, the Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment, and the score in the observation group was lower than that in the control group, differences being significant(P<0.05). After treatment, the levels of CD4 + and CD4 +/CD8 + in the observation group were increased when compared with those before treatment,and the level of CD8+ was decreased(P<0.05);the levels of CD4+ and CD4+/CD8+ in the control group were decreased when compared with those before treatment,and the level of CD8+ was increased (P<0.05). The levels of CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,and the level of CD8 + was lower(P<0.05). Before treatment, there was no significant difference being found in the comparison of Karnofsky scores between the two groups(P>0.05). After treatment,the Karnofsky scores in the two groups were increased when compared with those before treatment, and the score in the observation group was higher than that in the control group, differences being significant(P<0.05). Before treatment, there was no significant difference being found in the comparison of scores of quality of life between the two groups(P>0.05). After treatment,the scores of quality of life in the two groups were increased when compared with those before treatment,and the score in the observation group was higher than that in the control group,differences being significant(P<0.05). Conclusion:Jianpi Tongluo prescription combined with chemotherapy in treating patients with advanced esophageal carcinoma can effectively improve their clinical symptoms,immune function and quality of life.

    参考文献
    相似文献
    引证文献
引用本文

张寅刚,许吟枫.健脾通络方联合化疗对中晚期食管癌患者生活质量的影响[J].新中医,2020,52(10):108-111

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-05-26
  • 出版日期: